Physician profile
Mark E Allara
NPI 1659457984
$528.21
in general payments reported to CMS, 2019-2025
16 companies · $24.84 in 2025
The $24.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $90.27 · 2021: $113 · 2022: $16.54 · 2023: $15.29 · 2024: $32.67 · 2025: $24.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $149.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.70 | 2019 | |
| Boston Scientific Corporation | $32.67 | 2024 | |
| Amgen INC. | $32.50 | 2019 | |
| Pfizer INC. | $30.24 | 2019-2020 | |
| Allergan, INC. | $30.19 | 2020 | |
| Lilly USA, LLC | $26.27 | 2020-2021 | |
| Avion Pharmaceuticals | $25.16 | 2019 | |
| Astellas Pharma US INC | $24.84 | 2025 | Veozah |
| Abbvie INC. | $23.38 | 2021 | |
| Celgene Corporation | $20.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.28 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $15.29 | 2023 | Dsuvia |
| Gilead Sciences, INC. | $14.42 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.13 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Allara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.